Browsing by Subject "hypertrophy"
- Results Per Page
- Sort Options
Item Open Access MEF2 and the Right Ventricle: From Development to Disease.(Frontiers in cardiovascular medicine, 2019-01) Clapham, Katharine R; Singh, Inderjit; Capuano, Isabella S; Rajagopal, Sudarshan; Chun, Hyung JPulmonary arterial hypertension is a progressive and ultimately life-limiting disease in which survival is closely linked to right ventricular function. The right ventricle remains relatively understudied, as it is known to have key developmental and structural differences from the left ventricle. Here, we will highlight what is known about the right ventricle in normal physiology and in the disease state of pulmonary arterial hypertension. Specifically, we will explore the role of the family of MEF2 (myocyte enhancer factor 2) transcription factors in right ventricular development, its response to increased afterload, and in the endothelial dysfunction that characterizes pulmonary arterial hypertension. Finally, we will turn to review potentially novel therapeutic strategies targeting these pathways.Item Open Access Novel Roles for Fibroblast Growth Factor Homologous Factors in Caveolae-Mediated Cardioprotection(2016) Wei, EricFibroblast growth factor homologous factors (FHFs) are non-canonical members of the fibroblast growth factor family (FGF11-14) that were initially discovered to bind and regulate neuronal and cardiac voltage-gated Na+ channels. Loss-of-function mutations that disrupt interaction between FHFs and Na+ channels cause spinocerebellar ataxias and cardiac arrhythmias such as Brugada syndrome. Although recent studies in brain of FHF knockout mice suggested novel functions for FHFs beyond ion channel modulation, it is unclear whether FHFs in the heart serve additional roles beyond regulating cardiac excitability. In this study, we performed a proteomic screen to identify novel interacting proteins for FGF13 in mouse heart. Mass spectrometry analysis revealed an interaction between FGF13 and a complex of cavin proteins that regulate caveolae, membrane invaginations that organize protective signaling pathways and provide a reservoir to buffer membrane stress. FGF13 controls the relative distribution of cavin 1 between the plasma membrane and cytosol and thereby acts as a negative regulator of caveolae. In inducible, cardiac-specific Fgf13 knockout mice, cavin 1 redistributed to the plasma membrane and stabilized the caveolar structural protein caveolin 3, leading to an increased density of caveolae. In a transverse aortic constriction model of pressure overload, this increased caveolar abundance enhanced cardioprotective signaling through the caveolar-organized PI3 kinase pathway, preserving cardiac function and reducing fibrosis. Additionally, the increased caveolar reserve provided mechanoprotection, as indicated by reduced membrane rupture in response to hypo-osmotic stress. Thus, our results establish FGF13 as a novel regulator of caveolae-mediated mechanoprotection and adaptive hypertrophic signaling, and suggest that inhibition of FHFs in the adult heart may have cardioprotective benefits in the setting of maladaptive hypertrophy.